Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03463291|
Recruitment Status : Not yet recruiting
First Posted : March 13, 2018
Last Update Posted : March 13, 2018
Bone tumors are categorized according to their tissue of origin into cartilagenous, osteogenic, fibrogenic, fibrohistiocytic, haematopoietic, vascular, and lipogenic tumors.
Magnetic resonance imaging (MRI) is now indispensable for the preoperative workup and therapeutic follow-up of patients with musculoskeletal tumors.
The application of DW-MRI in bone marrow is today an established examination technique that provides a unique contrast and that can help in the detection of bone-marrow pathologies and the differentiation of benign and malignant bone-marrow lesions.
Diffusion MRI provides quantitative and qualitative assessments of tissue cellularity and cell-membrane integrity. It is widely used for tumour detection, characterisation, and monitoring during treatment. Diffusion MRI supplies functional information that complements the structural evaluation.
In combination with standard structural MRI parameters, the ADC value improves tumour characterization. Diffusion MRI can also be used to monitor tumours during chemotherapy. Tumour necrosis results in loss of cell membrane integrity and in expansion of the extracellular compartment, leading to greater water-molecule diffusion with an increase in the ADC value.
|Condition or disease||Intervention/treatment|
|Efficacy of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions||Device: MRI|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions|
|Estimated Study Start Date :||May 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||July 2020|
All patients with bony lesions
- The ADC value of MRI diffusion in benign and malignant bony lesions ( considering ADC value <1.2 ..malignant while ADC>1.2 ..benign) [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03463291
|Contact: Amr M Attiafirstname.lastname@example.org|